Click the play button below to stream the episode via SoundCloud!
This month on The BloodStream Podcast, Hemlibra is FDA approved and the first non-factor replacement therapy to treat people with hemophilia A (and inhibitors) is now on the market, we’ll discuss that along with other major product development takeaways from the American Society of Hematology’s Annual Meeting held earlier this month during our Comment Segment. Natalie will present a story on how new HIV guidelines are revolutionizing patients lives in the Like Segment, and Community Member Angel Parrett shares her story of living with Factor 1 deficiency in today’s Share Segment. Plus, Patrick sits down with National Hemophilia Foundation CEO Val Bias to review some of the major community highlights from 2017, and to look ahead at what’s to come in 2018. All that and more on Episode 19 of The BloodStream Podcast.
Exclusive Sponsor: Shire
Share Segment: Angel Parrett: One In A Million: Factor 1 Deficiency
Comment Segment: Hemlibra is FDA Approved & Major Takeaways from #ASH17
Other Links of Interest
Connect with BloodStream:
Find all of our bleeding disorders podcasts on BloodStreamMedia.com
Subscribe to BloodStream:
Google Play: http://bit.ly/bloodstreamPlay